Retinal photocoagulation laser Navilas® 577s

trabeculoplastyretinopexydiode

Navilas® is the only laser system on the market with proprietary OD-OS retinal navigation technology for image-guided precision in photocoagulation and microsecond pulse laser treatment. Clinics and practices in over 40 countries trust our yellow laser, which sets the standard for modern retinal treatment.

Key Features:
High Precision and Reliability à Precise laser application with wide-angle fundus view, eye tracking, and exclusion zones for enhanced protection (1)
Increased Speed ​​and Comfort à Faster patient treatment with less pain and interruptions thanks to computer-guided laser application (2)
Reproducible Subthreshold Treatments à Reproducible application of subthreshold treatments, as invisible effects are tracked and digitally visualized (3)
Improved Efficiency à Treat more patients in less time through rapid laser application, improved patient cooperation, and efficient use of team resources throughout the hospital stay (4)
Anterior Eye Mode à Treatment of open-angle glaucoma patients with non-invasive microsecond pulse laser trabeculoplasty (MLT)

Upgrades:
Contactless Treatment à Comfortable treatments up to the ora serrata – without a contact lens on the eye (5)
Integration into Digital Workflows à Planning treatments on imported FA or OCT images and secure Storage via DICOM/PACS connectivity
Multimodal reporting and database → Transparent visual reports for internal documentation, patients, and referring physicians (6)
Easy on-site training → Sharing expertise through simulation mode and live observation on the large treatment screen (7)
Expert teleguidance → Remote access to the treatment screen for live instruction and distance learning (7)

A modular platform that evolves
Our system was designed to redefine precision and speed. And it grows with your needs. With the Navilas® 577s, you can start with basic navigated procedures and expand them with advanced features—all on a single hardware platform. This ensures long-term value and clinical versatility.

(1) Kernt M et al. Clin Ophthalmol, 2012:289-296. & Kozak I et al. Ophthalmology2011;118(6):1119-1124.

(2) Amoroso F et al. Acta Diabetol, 2020;57:535-541. & Chhablani J et al. Invest Ophthalmol Vis Sci, 2014;55(6):3432-3438.

(3) Amoroso F et al. Eur J Ophthalmol, 2022;32(5):2810-2818. & Chhablani J et al. Int J Retina Vitreous, 2021;7:1-7.

(4) Video-Interview Dr. Lars Freisberg

(5) Shaimova VA et al. Vestn Oftalmol, 2021;137(1):46-52.

(6) Ambiya V et al. Clin Ophthalmol, 2016:1513-1519.

(7) Fassbender B. Retin Physician, 2017. & Ziegler M et al. Invest Ophthalmol Vis Sci, 2024;65(7):4202.